Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
Sponsor: Skingenix, Inc.
Summary
To compare MW-III to Silvadene® Cream 1% (Silver Sulfadiazine) with respect to "time to healing" (≥95% re-epithelialization) of a partial thickness target thermal burn.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2022-03-11
Completion Date
2026-12-31
Last Updated
2026-03-16
Healthy Volunteers
No
Conditions
Interventions
Investigational Drug, MW-III
Topical application, twice a day
Silvadene® Cream 1% [Silver Sulfadiazine]
Topical application, twice a day
Locations (6)
Valleywise Health Medical Center
Phoenix, Arizona, United States
University of CA Davis Medical Center
Sacramento, California, United States
MedStar Washington Hospital Center
Washington D.C., District of Columbia, United States
University of Iowa Health Care
Iowa City, Iowa, United States
Proactive CR Mexico SA de CV
Irapuato, Mexico
SMIQ S de R. L de CV
Querétaro City, Mexico